It may take a weight loss pill for Eli Lilly to finally meet demand for its popular anti-obesity medications, according to Eli Lilly’s top leader on weight loss drugs.The pharma giant is doing all it can to ramp up production of its highly-coveted diabetes and weight loss drugs,

Glucagon-like peptide 1 (GLP-1) weight-loss drugs such as Zepbound and Wegovy are growing in popularity. And that has made the companies who make those drugs, Eli Lilly and Novo Nordisk, hot investments over the past few years.

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

Novo Nordisk and Eli Lilly have been big players in the weight loss drug market for a while now. But their dominance might be challenged soon. Amgen is one of the companies trying to get into the market with its weight loss treatments.